TG Therapeutics (NASDAQ:TGTX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

TG Therapeutics (NASDAQ:TGTX) issued its earnings results on Monday. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01), Briefing.com reports. The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.73 EPS.

TG Therapeutics Stock Up 1.0 %

TGTX stock traded up $0.28 during mid-day trading on Thursday, hitting $27.45. 468,810 shares of the company were exchanged, compared to its average volume of 3,636,246. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. TG Therapeutics has a twelve month low of $9.81 and a twelve month high of $27.80. The firm has a fifty day simple moving average of $23.65 and a 200 day simple moving average of $20.30. The company has a market capitalization of $4.25 billion, a PE ratio of -271.70 and a beta of 2.19.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of research analyst reports. B. Riley increased their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright increased their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.